Cyrus Harmon, Director at Olema Pharmaceuticals, Inc. (OLMA), sold 25,000 shares at $12.57 ($314K) on 2023-11-30, disclosed to the SEC on 2023-12-01.
Scheduled sale ($314k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| OLMA | SELL | 2026-01-16 | $102K | — | Filing → |
| OLMA | SELL | 2025-12-29 | $164K | — | Filing → |
| OLMA | SELL | 2025-09-18 | $285K | — | Filing → |